Nektar Therapeutics (NKTR) Return on Capital Employed (2011 - 2026)

Nektar Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 6.25% for Q1 2026.

• In Q1 2026, Return on Capital Employed rose 4841.0% year-over-year to 6.25%; the TTM figure through Mar 2026 stood at 6.25% (up 4841.0% YoY), while the FY2025 annual figure was 14.45%, up 2188.0% from the prior year.
• Return on Capital Employed was 6.25% for Q1 2026 at Nektar Therapeutics, up from 14.53% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 6.25% in Q1 2026 to a low of 71.48% in Q4 2023.
• Historically, Return on Capital Employed has averaged 51.92% across 5 years, with a median of 55.51% in 2022.
• The sharpest annual moves came in 2022 and 2026: Return on Capital Employed sank 2539 bps in 2022, then jumped 4841 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 55.51% in 2022, then retreated by 29 bps to 71.48% in 2023, then jumped by 40 bps to 43.02% in 2024, then soared by 66 bps to 14.53% in 2025, then surged by 57 bps to 6.25% in 2026.
• The last three Return on Capital Employed figures came in at 6.25% (Q1 2026), 14.53% (Q4 2025), and 52.15% (Q3 2025), per Business Quant data.